1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Adhera Therapeutics Inc

Adhera Therapeutics Inc

ATRX
Adhera Therapeutics IncUS flagOther OTC
0.00
USD
- -
- -
722.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
280.02
70.67
62.86
24.97
4.06
5.17
- -
- -
0.14
0.46
- -
- -
- -
- -
Basic EPS, GAAP
-3,159.13
-929.93
-142.3
-18.55
-101.3
20.13
-3.53
-12.65
-32.88
-24.87
-9.76
-12.84
-0.92
-1.24
Free Cash Flow per Basic Share
-1,958.45
-509.47
-65.45
3.37
-38.8
-16.8
-2.2
-3.33
-17.87
-16.12
-1.08
-1.02
-0.61
-0.22
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,954.35
1.2
-83.89
-3,910.93
-2,741.17
-2,541.88
-8
-16.2
-47.58
-72.43
-81.91
-80.97
-24.15
-16.43
Tangible Book Value per Share
-633.47
-210.55
-183.77
-162.53
-89.88
-48.95
-11.18
-11.41
4.68
-18.24
-27.16
-38.35
-9.61
-7.21
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
2
4
Sales/Revenue/Turnover
2
2
4
2
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-1,057.07
-785.82
-147.07
-17.26
-704
-586.62
- -
- -
-13,972.37
-4,047.62
- -
- -
- -
- -
Depreciation Expense
2
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-28
-29
-10
-2
-6
3
-1
-6
-17
-12
-4
-6
-2
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
0.05
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,128.17
-1,315.92
-226.37
-74.28
-1,295.4
490.74
- -
- -
-22,046.05
-4,753.17
- -
- -
- -
- -
Working Capital
-3
-2
-5
-5
1
-2
-3
-6
2
-10
-15
-25
-22
-26
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
17
- -
-6
-7
-4
- -
3
- -
3
-10
-15
-25
-22
-26
Return on Invested Capital (%)
- -
- -
- -
- -
- -
198.76
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-0.99
- -
- -
- -
- -
- -
- -
- -
-21.85
Return on Common Equity (%)
- -
-342
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
10
11
11
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
4
5
Market Capitalization
1
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
23
23
26
Payables & Accruals
8
8
9
ST Debt
10
11
11
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
114.21%
44.59%
-11.63%
Free Cash Flow
-128.54%
102.99%
112.78%
Net Income, GAAP
66.93%
14.85%
-66.71%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-2.34
-0.88
-5.76
- -
-12.84
2022
-0.51
0.09
-0.57
- -
-0.92
2023
-0.29
0.08
-0.83
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
David A. Battat
Full Time Employees
2
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
8000 Innovation Parkway Baton Rouge LA United States of America 70820
IPO Date
Dec 7, 1993
CIK
0000737207
Website
adherathera.com
Similar Companies
Welcia Holdings Co., Ltd. (WLCGF)
PharmaRoth Labs, Inc. (ROTH)
Sibannac, Inc. (SNNC)
InNexus Biotechnology, Inc. (IXSBF)
MedPlus Health Services Limited (MEDPLUS.BO)
ProText Mobility, Inc. (TXTM)
Business
Adhera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel medicines for cardiometabolic diseases. The company's primary product offerings include pharmaceutical drug candidates and formulations targeting conditions such as diabetes, cardiovascular disease, and metabolic disorders. Adhera Therapeutics specializes in developing peptide therapeutics, sustained-release formulations, and innovative delivery technologies designed to optimize drug efficacy and patient adherence. The company operates primarily in the United States and targets the global biopharmaceutical market. Founded in 2015, Adhera Therapeutics is headquartered in Silicon Valley, California. Recent major developments include strategic collaborations with leading pharmaceutical firms aimed at co-developing and advancing its pipeline products through clinical trials. The company has also raised significant funding rounds within the last two years to expand its research capabilities and accelerate commercialization efforts. Additionally, Adhera has introduced new product formulations that incorporate proprietary delivery systems enhancing the therapeutic profile of its drug candidates. These strategic steps underscore Adhera Therapeutics' commitment to advancing innovative treatment options in the cardiometabolic therapeutic area and expanding its presence in key global markets. The company continues to focus on development-stage assets with the objective of delivering next-generation therapies that improve patient outcomes.

Company News

APIChatGPT

  • defenseworld.net

    CG Oncology (NASDAQ:CGON) vs. Adhera Therapeutics (OTCMKTS:ATRX) Critical Survey

  • globenewswire.com

    Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease

  • investorplace.com

    7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

  • globenewswire.com

    Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias